NOW APPROVED
Discover JIDEYTRO, a new therapy for TKI-pretreated ROS1+ NSCLC1
JIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.1
ROS1+=ROS proto-oncogene 1–positive; TKI=tyrosine kinase inhibitor.
Talk to a representative
Contact a Nuvalent representative to learn more about JIDEYTRO.